ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Shares Sold by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. lowered its stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) by 84.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 101,397 shares of the company’s stock after selling 551,651 shares during the quarter. Jacobs Levy Equity Management Inc.’s holdings in ARS Pharmaceuticals were worth $1,070,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS acquired a new stake in ARS Pharmaceuticals during the fourth quarter worth approximately $73,000. BNP Paribas Financial Markets acquired a new stake in ARS Pharmaceuticals during the fourth quarter worth approximately $75,000. Compass Capital Corp MA ADV acquired a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at $106,000. Teacher Retirement System of Texas acquired a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at $122,000. Finally, Graham Capital Management L.P. acquired a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at $132,000. Institutional investors and hedge funds own 68.16% of the company’s stock.

Wall Street Analysts Forecast Growth

SPRY has been the topic of a number of recent research reports. Scotiabank initiated coverage on shares of ARS Pharmaceuticals in a report on Friday, March 7th. They issued a “sector outperform” rating and a $30.00 target price on the stock. Oppenheimer initiated coverage on shares of ARS Pharmaceuticals in a report on Monday, February 10th. They issued an “outperform” rating and a $40.00 target price on the stock. Finally, William Blair reaffirmed an “outperform” rating on shares of ARS Pharmaceuticals in a report on Monday, March 3rd. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, ARS Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $31.00.

Insider Buying and Selling at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, Director Laura Shawver sold 49,600 shares of the business’s stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $11.21, for a total value of $556,016.00. Following the transaction, the director now directly owns 210,346 shares of the company’s stock, valued at approximately $2,357,978.66. The trade was a 19.08% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Eric Karas sold 10,000 shares of the business’s stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $14.00, for a total transaction of $140,000.00. Following the completion of the transaction, the insider now directly owns 7,696 shares in the company, valued at $107,744. This represents a 56.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 109,602 shares of company stock valued at $1,311,041. 33.50% of the stock is owned by company insiders.

ARS Pharmaceuticals Stock Performance

Shares of SPRY opened at $13.60 on Friday. The stock has a market capitalization of $1.34 billion, a P/E ratio of -26.67 and a beta of 0.84. The company’s fifty day moving average is $13.34 and its two-hundred day moving average is $12.89. ARS Pharmaceuticals, Inc. has a 1 year low of $7.55 and a 1 year high of $18.51.

ARS Pharmaceuticals (NASDAQ:SPRY) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.35). The firm had revenue of $7.97 million during the quarter, compared to analyst estimates of $7.48 million. Sell-side analysts predict that ARS Pharmaceuticals, Inc. will post -0.55 EPS for the current year.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.